Heatwurx (PCSA) News Today $0.19 +0.00 (+2.39%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$0.19 0.00 (0.00%) As of 07/3/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period HC Wainwright Issues Positive Forecast for Heatwurx EarningsJuly 4 at 2:35 AM | americanbankingnews.comQ1 Earnings Forecast for Heatwurx Issued By HC WainwrightJuly 3 at 2:33 AM | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for Heatwurx (NASDAQ:PCSA) Stock PriceJuly 2 at 2:03 AM | americanbankingnews.comProcessa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comProcessa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025June 13, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual MeetingMay 30, 2025 | globenewswire.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceFebruary 7, 2025 | globenewswire.comProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.comProcessa Pharmaceuticals director David Young buys $99,288 in stockJanuary 30, 2025 | msn.comProcessa Pharmaceuticals' chief business officer buys $34,691 in stockJanuary 30, 2025 | msn.comInsider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Acquires 87,200 Shares of StockJanuary 30, 2025 | insidertrades.comProcessa Pharmaceuticals prices $5M at-the-market offeringJanuary 29, 2025 | markets.businessinsider.comProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 27, 2025 | globenewswire.comProcessa Pharmaceuticals stock hits 52-week low at $0.65January 27, 2025 | msn.comProcessa Pharmaceuticals stock hits 52-week low at $0.8January 17, 2025 | msn.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 20, 2024 | markets.businessinsider.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 20, 2024 | markets.businessinsider.comProcessa Pharmaceuticals, Inc. (PCSA)November 21, 2024 | finance.yahoo.comProcessa Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 2, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Reports Third Quarter Business Highlights and Financial ResultsOctober 30, 2024 | markets.businessinsider.comBiotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness EffortsOctober 15, 2024 | theglobeandmail.comProcessa Pharmaceuticals maintains Buy rating from H.C. WainwrightOctober 5, 2024 | uk.investing.comBuy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-CapOctober 4, 2024 | markets.businessinsider.comProcessa Pharma (NASDAQ:PCSA) Stock, Short Interest ReportOctober 3, 2024 | benzinga.comProcessa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast CancerOctober 2, 2024 | globenewswire.comInvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024September 3, 2024 | msn.comProcessa Pharmaceuticals to Participate in Investor and Industry Conferences During SeptemberSeptember 3, 2024 | globenewswire.comProcessa Pharmaceuticals Provides Product Pipeline and Financial UpdateAugust 28, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Announces Positive Preclinical Data for NGC-IriAugust 19, 2024 | stockhouse.comAnalysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)August 19, 2024 | markets.businessinsider.comBioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-IriAugust 19, 2024 | msn.com3 Penny Stocks to Watch Now, 8/1/24August 2, 2024 | msn.comBuy Recommendation Reaffirmed on Processa Pharmaceuticals Following IND Clearance and Executive AppointmentJuly 31, 2024 | markets.businessinsider.comProcessa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast CancerJuly 30, 2024 | finance.yahoo.comFDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%July 30, 2024 | msn.comWhy Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?July 30, 2024 | investorplace.comProcessa Pharmaceuticals Names Russell Skibsted CFO - Quick FactsJuly 19, 2024 | markets.businessinsider.comProcessa Pharmaceuticals appoints CFOJuly 19, 2024 | msn.comProcessa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal CancerJune 11, 2024 | globenewswire.comProcessa Pharmaceuticals to Participate in the EF Hutton Annual Global ConferenceMay 6, 2024 | globenewswire.com Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address PCSA Media Mentions By Week PCSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCSA News Sentiment▼0.570.58▲Average Medical News Sentiment PCSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCSA Articles This Week▼111▲PCSA Articles Average Week Get Heatwurx News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aprea Therapeutics News GT Biopharma News Dogwood Therapeutics News Kiora Pharmaceuticals News AEON Biopharma News LakeShore Biopharma News Alaunos Therapeutics News Synaptogenix News Chromocell Therapeutics News Turnstone Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCSA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
